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Abstract: Problem statement: The Tigecycline Evaluation and Surveillance Trial (TEST) 
commenced in 2004 to monitor the activity of tigecycline, a new glycylcycline and numerous 
comparators against major hospital-and community-associated pathogens. In this report we examine 
the efficacy of tigecycline and comparators against isolates of Staphylococcus aureus collected from 
blood. Approach: Almost 4000 blood-derived isolates of Staphylococcus aureus were collected from 
participating centers globally between 2004-2008. Results: All isolates were susceptible to tigecycline 
(MIC90 0.25 mg L
−1) and linezolid (MIC90 4 mg L
−1); 99.9% of isolates were susceptible to 
vancomycin (MIC90 1 mg L
−1). Tigecycline and linezolid activity were unaffectd by resistance to 
methicillin, ICU vs non-ICU isolate collection or the age of patients from which the isolates were 
collected. Although 95.3% of MSSA were levofloxacin susceptible, only 14.4% of MRSA isolates 
were susceptible to levofloxacin in this study. Conclusion: Tigecycline is shown here to be active 
against S. aureus isolates collected from blood and is unaffected by methicillin resistance. However, 
tigecycline is not as yet approved for the treatment of bacteremic infections. 
 




 Antimicrobial resistance among a variety of 
bacterial pathogens is now well documented and is an 
increasingly important consideration when evaluating 
therapeutic choice and healthcare cost (McDonald, 2006; 
Chastre, 2008; Isturiz, 2008). Increases in antimicrobial 
resistance have led to increased patient morbidity and
mortality as well as increased length of hospital st y and 
health care costs (Cosgrove, 2006). The escalations in 
antimicrobial resistance have presented challenges to 
healthcare providers, making the selection of effectiv  
empiric therapy increasingly difficult (Deasy, 2009).  
 Staphylococcus aureus continues to be a common 
cause of serious infections, including those involving 
the bloodstream and antimicrobial therapy of this 
organism is complicated by the evolution of Methicillin 
(MRSA) and Multi-Drug (MDR) resistant strains 
(Lodise and McKinnon, 2005; Rehm et al., 2009). 
MRSA is an important risk factor for other serious 
illnesses, including novel H1N1 influenza infection 
(Shannon et al., 2009). MRSA can also be a 
significant contributor to mortality: Klein et al. (2007) 
estimated that 5500 MRSA-related deaths occurred 
annually in the US between 1999 and 2005, while the 
Office for national statistics in the UK has reported a 
maximum of 1629 MRSA-related deaths, occurring in 
2005 (Office for National Statistics, 2009). In 
Australia and New Zealand where invasive S. aureus 
infection is associated with substantial mortality, 
significant rates of MRSA and the suboptimal 
antimicrobials available for treatment of these strains 
have been shown  to exacerbate the problem 
(Turnidge et al., 2009).  
 Tigecycline (Wyeth Pharmaceuticals, Collegeville, 
PA, USA) is the first clinically available representative 
of a new class of antimicrobials, the glycylcyclines, 
which are derived from the tetracycline nucleus. 
Tigecycline (Fig. 1) is characterized by a broad spectrum 
of potent antibacterial activity and remains active against 
many strains expressing tetracycline and multi-drug 
resistance (Felmingham, 2005; Zhanel et al., 2006).  





Fig. 1: Structural formula of tigecycline 
 
 Antimicrobial susceptibility surveillance is an 
important strategy in understanding the evolution of 
antimicrobial resistance and providing information as
an aid to optimizing the empirical therapy of bacterial 
infections (Felmingham, 2002). The Tigecycline 
Evaluation and Surveillance Trial (TEST), established 
in 2004, is a global surveillance study designed to 
compare the in vitro activity of tigecycline with a panel 
of antimicrobials used in daily practice, against a range 
of   clinically   important  bacterial  species  including 
S. aureus. Tigecycline is indicated in the treatment of 
complicated Skin and Skin Structure Infections 
(cSSSIs), complicated Intra-Abdominal Infections 
(cIAIs) and Community-Acquired Bacterial Pneumonia 
(CABP) caused by penicillin-susceptible S. pneumoniae 
or β-lactamase negative H. influenzae (Wyeth 
Pharmaceuticals Inc, 2009a; 2009b). This study reports 
on the comparative in vitro susceptibility of 
bloodstream isolates of S. aureus examined during the 
sampling period 2004-2008. Tigecycline is not 
indicated for the treatment of bloodstream infections 
(Wyeth Pharmaceuticals Inc, 2009a; 2009b). 
 
MATERIALS AND METHODS 
 
Bacterial isolates: Bloodstream isolates of S. aureus 
were collected consecutively by centers participating in 
TEST, with only one isolate per patient included in the 
study. Data on a total of 3927 bloodstream isolates of 
S. aureus were submitted to the TEST during the period 
2004-2008. Of this total, 3629/3927 (92.4%) provided 
data enabling division of isolates into those sourced 
from patients treated on either non-ICU or ICU and 
3544/3927 (90.2%) could be separated into those 
patients aged 18-64 years and those ≥65 years of age 
(Table 1). 
 Collection, transport and confirmation of isolate 
identification were organized by Laboratories 
International for Microbiology Studies, a division of
International Health Management Associates (IHMA, 
Schaumburg, Ill., USA) which also managed a 
centralized database of isolate information. 
 Isolates were identified according to the American 
Society for Microbiology procedure for S. aureus 
(Murray, 2007). 
 
Antimicrobial susceptibility testing: Minimum 
Inhibitory Concentrations (MICs) of the antimicrobials 
included in the analysis were determined locally by 
participating centers using the Clinical Laboratory 
Standards Institute (CLSI) broth microdilution method 
(CLSI, 2009a) with either Microscan® panels (Dade 
Behring, Sacramento, Calif., USA) or Sensititre® plates 
(TREK Diagnostic Systems, East Grinstead, UK). 
Isolates of S. aureus were tested against the following 
antimicrobials (concentration ranges tested expressed 
in mg L−1): penicillin (0.06-8); amoxicillin/clavulanic 
acid (0.03/0.015-8/4); piperacillin/tazobactam (0.25/4-
16/4); ceftriaxone (0.03-64); imipenem (0.12-16, 
Microscan® only); meropenem (0.12-16, Sensititre® 
only); levofloxacin (0.06-32); linezolid (0.5-8); 
vancomycin (0.12-32); minocycline (0.25-8) and 
tigecycline (0.008-16). Imipenem was removed from 
the TEST and replaced by meropenem in 2006 because 
of imipenem stability issues. Quality control testing was 
carried out on each day of testing using S. aureus strain 
ATCC 29213. For all antimicrobials except tigecycline, 
MICs were interpreted using criteria published by the
CLSI (2009b). In the case  of  tigecycline, isolates of 
S. aureus requiring MIC of ≤0.5 mg L−1 were 
interpreted as susceptible, as recommended by the US 
Food and Drug Administration (Wyeth Pharmaceuticals 
Inc, 2009a; 2009b). 
 
Determination of methicillin resistance: All isolates 
of S. aureus were tested for the methicillin-resistant 
phenotype using the cefoxitin disk diffusion method 
(30 µg disks; Remel, Lenexa, KA, USA) by IHMA’s 
central laboratory (Murray, 2007). 
 
Quality assurance: All isolates were subjected to a 
Quality Assurance Programme (QAP) designed by 
IHMA, which incorporated more than 150 individual 
QA checks to screen for atypical susceptibility patterns 
or other discrepant results. In the case of S. aureus, 
some of these  checks  included tigecycline MIC 
>0.25 mg L−1, penicillin-susceptible and carbapenem or 
any beta-lactam-resistance and non-susceptibility to 
linezolid or vancomycin; some specific checks for 
MRSA were non-resistance to penicillin, susceptibili y 
to carbapenems and resistance to amoxicillin/clavulanic 
acid and non-susceptibility to quinupristin/dalfopristin.  
 Isolates with atypical results were re-evaluated 
with regard to  purity and identification followed by 
re-testing by the central laboratory using the same 
antimicrobial  panel  supplied  to  the  investigator  labs. 
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Table 1: Comparative distribution of MRSA amongst blood isolates of Staphylococcus aureus cultured from non-ICU and ICU patients and 
patients of 18-64 or ≥65 years of age, examined in the TEST programme, 2004- 08 
Year(s) of study 2004 2005 2006 2007 2008 2004-2008 
Non-ICU and ICU patient isolates 495 658 772 1063 641 3629 
S. aureus from non-ICU patients (%) 393 (79.4) 505 (76.7) 603 (78.1) 847 (79.7) 495 (77.2) 2843 (78.3) 
MRSA from non-ICU patients (%) 171 (43.5) 232 (45.9) 234 (38.8) 285 (33.6) 163 (32.9) 1085 (38.2) 
S. aureus from ICU patients (%) 102 (20.6) 153 (23.3) 169 (21.9) 216 (20.3) 146 (22.8) 786 (21.7) 
MRSA from ICU patients (%) 54 (52.9) 70 (45.8) 80 (47.3) 99 (45.8) 55 (37.7) 358 (45.5) 
Isolates from patients aged 18-64 and ≥65 years 478  633  740  1033  660  3544 
S. aureus from patients aged 18-64 years (%) 259 (54.2) 355 (56.1) 391 (52.8) 577 (55.9) 368 (55.8) 1950 (55.0) 
MRSA from patients aged 18-64 years (%) 112 (43.2) 155 (43.7) 143 (36.6) 209 (36.2) 102 (27.7) 721 (37.0) 
S. aureus from patients aged ≥65 years (%) 219 (45.8) 278 (43.9) 349 (47.2) 456 (44.1) 292 (44.2) 1594 (45.0) 
MRSA from patients aged ≥65 years (%) 113 (51.6) 136 (48.9) 162 (46.4) 187 (41.0) 116 (39.7) 714 (44.8) 
 
Isolates generating atypical results on retesting were 
reviewed by an in-house panel of microbiologists and 
either accepted and re-inserted into the database or r -
tested a second time. Atypical results generated on 





 Bloodstream isolates of S. aureus submitted to 
TEST and reported in this study were collected from 
centers in the following regions during the period 2004-
2008: Africa, the Asia/Pacific Rim, Europe, Latin 
America, the Middle East and North America (Fig. 2). In 
view of the relatively small numbers of isolates 
submitted annually from individual regions (with the 
exception of methicillin resistance) susceptibility data are 
reported on combined isolates from all years and regions. 
 While isolates of S. aureus from patients treated on 
non-ICU outnumber those from ICU almost 4-fold (2843 
(78.3%) Vs 786 (21.7%)), isolates from patients aged 18-
64 years and from those of ≥65 years are more evenly 
distributed (1950 (55.0%) Vs 1594 (45%)) (Table 1). 
 Overall rates of methicillin resistance (MRSA) are 
somewhat higher in patients treated in ICUs compared 
with the non-ICU setting (45.5% Vs 38.2%, 
respectively) (Table 1). 
 Of the combined total of 3927 bloodstream isolates 
of Staphylococcus aureus submitted to TEST during the 
period 2004-2008, 2397 (61.0%) are methicillin 
susceptible (MSSA) and 1530 are MRSA (Table 2). 
All isolates of MSSA and MRSA are susceptible to 
tigecycline (MIC90 0.25 mg L
−1; MIC100 0.5mg L
−1) 
and linezolid (MIC90 4 mg L
−1; MIC100 4 mg L
−1). 
Predictably, tigecycline retains activity against the 
small number of isolates not fully susceptible to 
minocycline. Most (99.9%) of the isolates of MSSA 
and of MRSA are susceptible to vancomycin with only 
three isolates of MSSA and one of MRSA requiring an 
MIC of 4 mg L−1, 2 fold greater than the susceptibility 
breakpoint of 2 mg L−1 (but not above the CLSI-defined 
resistant breakpoint of 16 mg L−1) (Table 2). 
 
 
Fig. 2: Geographical distribution of blood isolates of 
methicillin-susceptible (MSSA) and methicillin-
resistant Staphylococcus aureus (MRSA) 
examined in the TEST programme: 2004-2008 
combined isolates 
 
 While only 17.6% of isolates of MSSA are 
susceptible to penicillin, the staphylococcal beta-
lactamase-stable compounds included in the study are 
generally highly active against these strains 
(amoxicillin/clavulanic acid, 99.9% of isolates tested 
susceptible; piperacillin/tazobactam, 100% susceptible; 
ceftriaxone, 98.9% susceptible; imipenem, 99.9% of 
945 isolates tested susceptible; meropenem, 99.9% of 
1452 susceptible) (Table 2). All isolates of MRSA are 
considered clinically resistant to these compounds 
according to CLSI guidelines (CLSI, 2009a: 2009b). 
 The most obvious difference in susceptibility 
between MSSA and MRSA is with the fluoroquinolone, 
levofloxacin. Most (95.3%) isolates of MSSA are 
susceptible to this compound, compared with only 14.4% 
of MRSA (Table 2). Levofloxacin susceptibility 
increased significantly among S. aureus isolates from 
blood between 2004 (59.2% S) and 2008 (68.7% S) 
(p<0.0001. MRSA susceptibility to levofloxacin 
increased (p = 0.001) while MSSA susceptibility 
decreased (p = 0.0167) during this interval. Data for 
2008 are incomplete at this point, however, so the 
reliability of these trends is uncertain. 
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Table 2: Comparative in vitro activity of tigecycline against 3927 blood isolates of Staphylococcus aureus examined in the TEST programme, 
2004-2008 
 MSSA MIC (mg L−1)    MRSA MIC (mg L−1) 
 -------------------------------------------------------------- -------------------------------------------------------------------- 
Antimicrobial n 50% 90% Range S (%) n 50% 90% Range S (%) 
Penicillin 2397 4.00 ≥16.00 ≤0.06-≥16 17.6 1530 ≥16.00 ≥16.00 0.25-≥16 0.0* 
Amoxycillin/clavulanic acid 2397 1.00 2.00 ≤0.03-8 99.9 1530 8.00 ≥16.00 0.25-≥16 0.0* 
Piperacillin/tazobactam 2397 1.00 2.00 ≤0.25-8 100.0 1530 ≥32.00 ≥32.00 ≤0.25-≥32 0.0* 
Ceftriaxone 2397 2.00 4.00 0.25-≥128 98.9 1530 64.00 ≥128.00 ≤0.03-≥128 0.0* 
Imipenem 945 ≤0.12 0.25 ≤0.12-8 99.9 717 1.00 ≥32.00 ≤0.12-≥32 0.0* 
Meropenem 1452 ≤0.12 0.25 ≤0.12-8 99.9 813 4.00 ≥32.00 ≤0.12-≥32 0.0* 
Levofloxacin 2397 0.12 0.50 ≤0.06-≥64 95.3 1530 8.00 ≥64.00 ≤0.06-≥64 14.4 
Linezolid 2397 2.00 4.00 ≤0.5-4 100.0 1530 2.00 4.00 ≤0.5-4 100.0 
Vancomycin 2397 1.00 1.00 ≤0.12-4 99.9 1530 1.00 1.00 ≤0.12-4 99.9 
Minocycline 2397 ≤0.25 0.50 ≤0.25-≥16 99.4 1530 ≤0.25 4.00 ≤0.25-≥16 94.4 
Tigecycline 2397 0.12 0.25 0.015-0.5 100.0 1530 0.12 0.25 ≤0.008-0.5 100.0 
*: All MRSA defined as resistant to penicillinase-labile penicillins, according to CLSI guidelines (11) 
 
Table 3: Comparative in vitro activity of tigecycline against 3629 blood isolates of Staphylococcus aureus from non-ICU and ICU patients 
examined in the TEST programme, 2004-2008  
 Non-ICU patient isolates MIC (mg L−1)  ICU patient isolates MIC (mg L−1) 
 ------------------------------------------------------------------- --------------------------------------------------------------------- 
Antimicrobial n 50% 90% Range S (%) n 50% 90% Range S (%) 
Methicillin-suceptible isolates  
Penicillin 1758 4.00 ≥16.00 ≤0.06-≥16 17.6 428 8.00 ≥16.00 ≤0.06-≥16 16.8 
Amoxycillin/clavulanic acid 1758 1.00 2.00 ≤0.03-8 99.9 428 1.00 2.00 0.06-8 99.8 
Piperacillin/tazobactam 1758 1.00 2.00 ≤0.25-8 100.0 428 1.00 1.00 ≤0.25-8 100.0 
Ceftriaxone 1758 2.00 4.00 0.25-≥128 99.1 428 2.00 4.00 0.25-≥128 97.9 
Imipenem 697 ≤0.12 0.25 ≤0.120-1 100.0 179 ≤0.12 0.25 ≤0.12-8 99.4 
Meropenem 1061 ≤0.12 0.25 ≤0.12-8 99.8 249 ≤0.12 0.25 ≤0.12-4 100.0 
Levofloxacin 1758 0.12 0.50 ≤0.06-≥64 94.9 428 0.12 0.50 ≤0.06-32 96.7 
Linezolid 1758 2.00 4.00 ≤0.5-4 100.0 428 2.00 2.00 ≤0.5-4 100.0 
Vancomycin 1758 1.00 1.00 ≤0.12-4 99.9 428 1.00 1.00 ≤0.12-4 99.8 
Minocycline 1758 ≤0.25 0.50 ≤0.25-≥16 99.5 428 ≤0.25 0.50 ≤0.25-≥16 98.8 
Tigecycline 1758 0.12 0.25 0.03-0.5 100.0 428 0.12 0.25 0.015-0.5 100.0 
Methicillin-resistant isolates  
Levofloxacin 1085 16.00 ≥64.00 ≤0.06-≥64 13.9 358 8.00 ≥64.00 ≤0.06-≥64 14.8 
Linezolid 1085 2.00 4.00 ≤0.5-4 100.0 358 2.00 2.00 ≤0.5-4 100.0 
Vancomycin 1085 1.00 1.00 ≤0.12-4 99.9 358 1.00 1.00 ≤0.12-2 100.0 
Minocycline 1085 ≤0.25 4.00 ≤0.25-≥16 94.8 358 ≤0.25 4.00 ≤0.25-≥16 91.9 
Tigecycline 1085 0.12 0.25 ≤0.008-0.5 100.0 358 0.12 0.25 ≤0.008-0.5 100.0
 
Table 4: Comparative in vitro activity of tigecycline against 3544 blood isolates of Staphylococcus aureus from patients aged 18-64 years and 
≥65 years examined in the TEST programme, 2004-2008 
 Patients aged 18-64 years MIC (mg L−1)   Patients aged ≥65 years MIC (mg L−1) 
 ----------------------------------------------------------------- --------------------------------------------------------------- 
Antimicrobial n 50% 90% Range S (%) n 50% 90% Range S (%) 
Methicillin-susceptible isolates  
Penicillin 1229 4.00 ≥16.00 ≤0.06-≥16 16.7 880 4.00 ≥16.00 ≤0.06-≥16 19.9 
Amoxycillin/clavulanic acid 1299 1.00 2.00 0.06-8 99.8 880 0.50 1.00 ≤0.03-8 99.9 
Piperacillin/tazobactam 1299 1.00 2.00 ≤0.25-8 100.0 880 1.00 1.00 ≤0.25-8 100.0 
Ceftriaxone 1299 2.00 4.00 0.5-≥128 98.9 880 2.00 4.00 0.25-16 99.1 
Imipenem 473 ≤0.12 0.25 ≤0.12-8 99.8 365 ≤0.12 0.25 ≤0.12-1 100.0 
Meropenem 756 ≤0.12 0.25 ≤0.12–8 99.7 515 ≤0.12 0.25 ≤0.12-4 100.0 
Levofloxacin 1299 0.12 0.50 ≤0.06-≥64 95.9 880 0.12 0.50 ≤0.06-≥64 94.5 
Linezolid 1299 2.00 4.00 ≤0.5-4 100.0 880 2.00 4.00 ≤0.5-4 100.0 
Vancomycin 1299 1.00 1.00 ≤0.12-4 99.8 880 1.00 1.00 ≤0.12-4 99.9 
Minocycline 1299 ≤0.25 0.50 ≤0.25-≥16 99.2 880 ≤0.25 ≤0.25 ≤0.25-≥16 99.7 
Tigecycline 1299 0.12 0.25 0.03-0.5 100.0 880 0.12 0.25 0.015-0.5 100.0 
Methicillin-resistant isolates 
Levofloxacin 721 8.00 ≥64.00 ≤0.06-≥64 17.9 714 16.00 ≥64.00 ≤0.06-≥64 6.7 
Linezolid 721 2.00 4.00 ≤0.5-4 100.0 714 2.00 4.00 ≤0.5-4 100.0 
Vancomycin 721 1.00 1.00 ≤0.12-2 100.0 714 1.00 1.00 0.25-4 99.9 
Minocycline 721 ≤0.25 4.00 ≤0.25-≥16 93.5 714 ≤0.25 4.00 ≤0.25-≥16 95.1 
Tigecycline 721 0.12 0.25 0.03-0.5 100.0 714 0.12 0.25 ≤0.008-0.5 100.0 
 
 With the exception of methicillin resistance, no 
major differences are evident when comparing 
susceptibility data of bloodstream isolates of S. aureus 
(MSSA and MRSA) from non-ICU and ICU settings 
(Table 3). 
 No major differences in susceptibility are observed 
when comparing isolates from patients aged 18-64 
years and ≥65 years of age with the exception of 
levofloxacin against MRSA. In the case of this 
fluoroquinolone, while 17.9% of those isolates from 
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patients aged 18-64 years are susceptible, only 6.7% 
among isolates from patients aged ≥65 years are 




 Bloodstream infection is a serious medical 
condition associated with high mortality, which can be 
reduced by initiation of prompt and appropriate 
empirical antimicrobial therapy (Bates et al., 1995; 
Mylotte et al., 2001; Hanon et al., 2002). S. aureus is a 
serious cause of bacteremia and successful treatment of 
this important pathogen is complicated by methicillin 
and multi-drug resistance, with rates of resistance 
higher amongst isolates cultured from patients in ICU 
rather than non-ICU settings and also from the elderly 
(Safdar and Maki, 2002; Cosgrove t al., 2003; 
Biedenbach et al., 2004; Cosgrove, 2006). MRSA 
bacteraemia has been shown to be more life threatening 
than MSSA due to the inferior efficacy of vancomycin 
which remains the standard treatment of serious MRSA 
infections in many countries (Turnidge et al., 2009). 
Against this background, continuing surveillance of the 
antimicrobial susceptibility of bacterial pathogens, 
including S. aureus and the development and 
characterization of new compounds are essential 
(Zinner, 2005; Zhanel et al., 2008). 
 Most pharmaceutical and biotechnology companies 
have reduced or ceased development of new 
antimicrobial agents in recent years, despite the 
continual threat to public health caused by the 
increasing prevalence of antibacterial resistance. One 
key reason is that considerably larger profits can be 
made through the development and sale of drugs for 
chronic medical conditions (Infectious Diseases Society 
of America, 2004; Payne t al., 2007). Tigecycline is 
one of a small number of new antimicrobials to have 
undergone successful clinical development recently and 
was licensed by the Food and Drug Administration 
(FDA) of the USA in 2005 and by the European 
Medicines Agency (EMEA) in 2006 for use in the 
treatment of complicated skin and skin structure 
infections and complicated intra-abdominal infections 
caused by a variety of susceptible bacterial pathogens 
including MSSA and MRSA (European Medicines 
Agency, 2009; Wyeth Pharmaceuticals Inc, 2009a; 
2009b). Tigecycline is unaffected by the majority of 
clinically important resistance mechanisms, including 
those two key in the expression of tetracycline 
resistance-ribosomal protection and efflux pumps-and 
methicillin resistance in staphylococci. TEST was 
established in 2004 as a global surveillance programme 
designed to monitor the in vitro activity of tigecycline 
and to compare it with that of other antimicrobials in 
common clinical use against a wide range of bacterial 
species, including antimicrobial-resistant strains 
(Wyeth Pharmaceuticals Inc, 2009a; 2009b). 
 In this study, we have reported on the susceptibility 
of bloodstream isolates of S. aureus to tigecycline and a 
range of comparator compounds, collected by centers 
worldwide and submitted to the TEST programme 
during the period 2004-2008. All of the isolates of 
Staphylococcus aureus included in the study, whether 
MSSA or MRSA strains, were inhibited by tigecycline 
at a concentration of 0.5 mg L−1 or less, indicating 
clinical susceptibility regardless of the activity of 
comparators. 
 Antimicrobial resistance is more likely to be 
encountered among bacterial isolates cultured from 
patients treated on ICUs and those considered elderly 
(Safdar and Maki, 2002; Biedenbach et al., 2004). 
There is some evidence for this in the case of 
methicillin resistance among the combined isolates 
(non-ICU Vs ICU isolates, MRSA occurrence = 38.2% 
Vs 45.5%;  age 18-64 Vs ≥65 years, MRSA 
occurrence = 37.0% Vs 44.8%). However, since no 
representatives of the aminglycosides, the macrolides 
or inhibitors of folate synthesis were tested, coupled 
with the fact that all isolates were susceptible to 
linezolid and at least 99.8% to vancomycin, the 
association between resistance and whether isolates 
were sourced from ICU and the elderly patients could 
not be tested robustly in this study. 
 Staphylococcus aureus susceptibility to the 
fluoroquinolone levofloxacin increased significantly 
during the course of this study, with increasing MSSA 
susceptibility and decreasing MRSA susceptibility 
reported between 2004 and 2008. One possible 
explanation for this is real change in S. aureus 
susceptibility brought on by more judicious use of beta-
lactam antibiotics in recent years. As awareness of the 
risks of MRSA increases, current treatment regimens 
may exert less selective pressure on the mecA genes 
which cause methicillin resistance. Continued 
observation of MRSA susceptibility rates via 
surveillance studies such as TEST will reveal if ths 
trend continues.  
 The development of new antimicrobials unaffected 
by current, commonly occurring mechanisms of 
resistance is of critical importance if the advantages of 
infection control, made possible by antimicrobial 
therapy and prophylaxis during the past 50 years, are to 




 Tigecycline is indicated in the treatment of 
cSSSIs, cIAIs and CABP caused by penicillin-
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susceptible  S.  pneumoniae or β-lactamase negative 
H. influenzae. Although tigecycline is not indicated for 
the treatment of bloodstream infections, the results of 
this analysis of bloodstream isolates of S. aureus 
submitted to the TEST programme during the period 
2004-2008 clearly demonstrate the potent activity of 
tigecycline and indicate its potential in the treatment of 
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